1 to 10 of 32 literature results

• Are the pleiotropic effects of telmisartan clinically relevant?

  Hypertension is one of the major risk factors for cardiovascular disease. Angiotensin receptor blockers (ARBs) are a class of antihypertensive drugs w…

  Authors: C V Rizos, M S Elisaf, E N Liberopoulos

  Source: Current pharmaceutical design. 2009

  View Full Text

• Drug combinations for dyslipidemia and obesity treatment in metabolic syndrome.

  Metabolic syndrome (MetS) is a cluster of risk factors, each one individually associated with increased cardiovascular disease risk. Treatment of all …

  Authors: M Florentin, M S Elisaf, D P Mikhailidis, E N Liberopoulos

  Source: Current pharmaceutical design. 2009

  View Full Text

• Fibrate-associated adverse effects beyond muscle and liver toxicity.

  Fibrate derivatives have a 40-year history in the management of dyslipidemia. Although this class of drugs is generally well tolerated, several safety…

  Authors: M Florentin, E N Liberopoulos, D P Mikhailidis, M S Elisaf

  Source: Current pharmaceutical design. 2008

  View Full Text

• Fibrinogen: a predictor of vascular disease.

  Raised plasma fibrinogen levels are associated with an increased risk of vascular events. This may be mediated by adverse effects of fibrinogen on pla…

  Authors: A I Kakafika, E N Liberopoulos, D P Mikhailidis

  Source: Current pharmaceutical design. 2007

  View Full Text

• Persistence of an atherogenic lipid profile after treatment of acute infection with brucella.

  Serum lipid changes during infection may be associated with atherogenesis. No data are available on the effect of Brucellosis on lipids. Lipid paramet…

  Authors: F Apostolou, I F Gazi, A Kostoula, C C Tellis, A D Tselepis, M Elisaf, E N Liberopoulos

  Source: Journal of lipid research. 2009 Dec

  View Full Text

• Effects of hormonal treatment on lipids in patients with cancer.

  Patients with malignant disease may need hormonal therapy as primary or adjuvant treatment or for palliation. Oestrogens usually decrease serum levels…

  Authors: T D Filippatos, E N Liberopoulos, N Pavlidis, M S Elisaf, D P Mikhailidis

  Source: Cancer treatment reviews. 2009 Apr

  View Full Text

• Do statins have an antiarrhythmic activity?

  Sudden cardiac death, which is mainly associated with the presence of life-threatening ventricular arrhythmias, is a common 'killer' among patients wi…

  Authors: M S Kostapanos, E N Liberopoulos, J A Goudevenos, D P Mikhailidis, M S Elisaf

  Source: Cardiovascular research. 2007 Jul 1

  View Full Text

• Statins and solid organ transplantation.

  Dyslipidaemia is common in solid organ transplant recipients and its presence is associated with chronic rejection and accelerated atherosclerosis, le…

  Authors: I F Gazi, E N Liberopoulos, V G Athyros, M Elisaf, D P Mikhailidis

  Source: Current pharmaceutical design. 2006

  View Full Text

• Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia.

  OBJECTIVE: Hypercholesterolaemia is a major risk factor for atherosclerosis and coronary heart disease. Treatment with lipid lowering agents reduces t…

  Authors: M Florentin, E N Liberopoulos, D P Mikhailidis, M S Elisaf

  Source: Current medical research and opinion. 2008 Apr

  View Full Text

• The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome.

  BACKGROUND: Increased concentration of small dense LDL cholesterol (sdLDL-C) and activity of lipoprotein-associated phospholipase A2 (Lp-PLA(2)) are c…

  Authors: T D Filippatos, I F Gazi, E N Liberopoulos, V G Athyros, M S Elisaf, A D Tselepis, D N Kiortsis

  Source: Atherosclerosis. 2007 Aug

  View Full Text